Platform efficacy
Construct efficacy
Adjuvant efficacy
Notes:
For detailed methods/citation please see Houlder et. al. 2025 (ADD PAPER CITATION HERE).
Contact: Emma L. Houlder, e.l.houlder@lumc.nl for feedback/comments.
Crosnier et. al. 2019 (PMID: 31728414) not included by default as tested 96 candidates so tends to dominate overview graphs (feel free to add and see!).
Emma L. Houlder was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (101063914). The work was also supported by funding from the European Union [Project 101080784 - WORMVACS2.0]. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority (HADEA) can be held responsible for them.
For detailed methods/citation please see Houlder et. al. 2025 (ADD PAPER CITATION HERE).
Contact: Emma L. Houlder, e.l.houlder@lumc.nl for feedback/comments.
Crosnier et. al. 2019 (PMID: 31728414) not included by default as tested 96 candidates so tends to dominate overview graphs (feel free to add and see!).
Emma L. Houlder was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (101063914). The work was also supported by funding from the European Union [Project 101080784 - WORMVACS2.0]. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority (HADEA) can be held responsible for them.